R W Kubiak1, J T Herbeck2, S M Coleman3, D Ross4, K Freedberg5, I V Bassett6, P K Drain7. 1. Epidemiology, and. 2. Global Health, University of Washington, Seattle, Washington. 3. Boston University School of Public Health, Boston, Massachusetts, USA. 4. Department of Medicine, St Mary's Hospital, Durban, South Africa. 5. Boston University School of Public Health, Boston, Massachusetts, USA, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 6. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 7. Epidemiology, and, Global Health, University of Washington, Seattle, Washington, Department of Medicine, University of Washington, Seattle, Washington, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
SETTING: Four ambulatory clinics in Durban, South Africa. OBJECTIVE: To test the relationships of patient characteristics, time to mycobacterial culture positivity, and mortality with urinary lipoarabinomannan (LAM) grade category. DESIGN: Newly diagnosed human immunodeficiency virus (HIV) infected adults were screened for tuberculosis (TB) using sputum culture, tested for urinary LAM, and followed for up to 12 months. We performed multivariable ordinal logistic regression of risk factors for low (1 or 2) or high (3, 4, or 5) LAM grade. We used adjusted Cox regression models to determine the hazard ratios of time to culture positivity and death. RESULTS: Among 683 HIV-infected adults, median CD4 count was 215 cells/mm³ (interquartile range 86-361 cells/mm³), 17% had culture-confirmed TB, and 11% died during follow-up. Smoking, tachycardia (pulse > 100 beats/minute), CD4 count < 100 cells/mm³, and TB culture positivity were each associated with higher LAM grade. In multivariate models, a high urine LAM grade was associated with four-fold increased hazard of culture positivity (P = 0.001) and two-fold increased hazard of mortality (P = 0.02). Among patients treated for TB, these associations were no longer statistically significant. CONCLUSION: In this population, a higher urine LAM grade was associated with shorter time to culture positivity and mortality; however, these associations were not present for those starting anti-tuberculosis treatment.
SETTING: Four ambulatory clinics in Durban, South Africa. OBJECTIVE: To test the relationships of patient characteristics, time to mycobacterial culture positivity, and mortality with urinary lipoarabinomannan (LAM) grade category. DESIGN: Newly diagnosed human immunodeficiency virus (HIV) infected adults were screened for tuberculosis (TB) using sputum culture, tested for urinary LAM, and followed for up to 12 months. We performed multivariable ordinal logistic regression of risk factors for low (1 or 2) or high (3, 4, or 5) LAM grade. We used adjusted Cox regression models to determine the hazard ratios of time to culture positivity and death. RESULTS: Among 683 HIV-infected adults, median CD4 count was 215 cells/mm³ (interquartile range 86-361 cells/mm³), 17% had culture-confirmed TB, and 11% died during follow-up. Smoking, tachycardia (pulse > 100 beats/minute), CD4 count < 100 cells/mm³, and TB culture positivity were each associated with higher LAM grade. In multivariate models, a high urine LAM grade was associated with four-fold increased hazard of culture positivity (P = 0.001) and two-fold increased hazard of mortality (P = 0.02). Among patients treated for TB, these associations were no longer statistically significant. CONCLUSION: In this population, a higher urine LAM grade was associated with shorter time to culture positivity and mortality; however, these associations were not present for those starting anti-tuberculosis treatment.
Authors: Jonathan G Peter; Grant Theron; Richard van Zyl-Smit; Asheen Haripersad; Lynelle Mottay; Sarah Kraus; Anke Binder; Richard Meldau; Anneli Hardy; Keertan Dheda Journal: Eur Respir J Date: 2012-02-23 Impact factor: 16.671
Authors: Stephen D Lawn; Andrew D Kerkhoff; Rosie Burton; Charlotte Schutz; Andrew Boulle; Monica Vogt; Ankur Gupta-Wright; Mark P Nicol; Graeme Meintjes Journal: BMC Med Date: 2017-03-21 Impact factor: 8.775
Authors: Paul K Drain; Elena Losina; Sharon M Coleman; Janet Giddy; Douglas Ross; Jeffrey N Katz; Rochelle P Walensky; Kenneth A Freedberg; Ingrid V Bassett Journal: BMC Infect Dis Date: 2014-02-26 Impact factor: 3.090
Authors: Yukari C Manabe; Bareng A S Nonyane; Lydia Nakiyingi; Olive Mbabazi; Gloria Lubega; Maunank Shah; Lawrence H Moulton; Moses Joloba; Jerrold Ellner; Susan E Dorman Journal: PLoS One Date: 2014-07-07 Impact factor: 3.240
Authors: Juan Ignacio García; Johanna Meléndez; Rosa Álvarez; Carlos Mejía-Chew; Holden V Kelley; Sabeen Sidiki; Alejandra Castillo; Claudia Mazariegos; Cesar López-Téllez; Diana Forno; Nancy Ayala; Joan-Miquel Balada-Llasat; Carlos Rodolfo Mejía-Villatoro; Shu-Hua Wang; Jordi B Torrelles; Janet Ikeda Journal: AIDS Res Ther Date: 2020-10-19 Impact factor: 2.846